BriaCell Therapeutics Corp. (BriaCell) is an immuno-oncology company which develops immunotherapy treatments for cancer. BriaCell is currently focused on the clinical development of BriaVax™ as a 2nd line treatment for patients with advance forms of breast cancer. In two Phase I clinical trials in Stage IV breast cancer patients who had failed prior treatments, the lifespan of the patients was significantly extended by BriaVax™ in some cases by fivefold. The tumor regression occurred rapidly with few side effects. Additionally, tumor regression was observed in other sites including the lung and the brain.